Key Points
-
Glucocorticoid use is associated with an increase in fracture risk that can begin early in the course of therapy, linked with both daily and cumulative dose
-
Reduced bone formation and increased cortical porosity are key pathogenetic features of glucocorticoid-induced osteoporosis (GIOP)
-
The underlying disease also contributes to bone loss and increased fracture risk in glucocorticoid-treated patients
-
Early, preventive anti-osteoporosis measures, based on FRAX®-related intervention thresholds, are recommended for patients receiving chronic glucocorticoid therapy
-
Lifestyle and nutritional measures advocated for patients with GIOP are identical to those for patients with primary osteoporosis
-
Pharmacological anti-osteoporotic therapy could be stopped upon withdrawal of glucocorticoids unless the patient remains at increased risk of fracture
Abstract
Among the adverse events of glucocorticoid treatment are bone loss and fractures. Despite available, effective preventive measures, many patients receiving or initiating glucocorticoid therapy are not appropriately evaluated and treated for bone health and fracture risk. Populations with, or at risk of, glucocorticoid-induced osteoporosis (GIOP) to target for these measures are defined on the basis of dose and duration of glucocorticoid therapy and bone mineral density. That patients with GIOP should be treated as early as possible is generally agreed upon; however, diversity remains in intervention thresholds and management guidelines. The FRAX® algorithm provides a 10-year probability of fracture that can be adjusted according to glucocorticoid dose. There is no evidence that GIOP and postmenopausal osteoporosis respond differently to treatments. Available anti-osteoporotic therapies such as anti-resorptives including bisphosphonates and the bone anabolic agent teriparatide are effective for the management of GIOP. Prevention with calcium and vitamin D supplementation is less effective than specific anti-osteoporotic treatment. Anti-osteoporotic treatment should be stopped at the time of glucocorticoid cessation, unless the patient remains at increased risk of fracture.
Similar content being viewed by others
References
van Staa, T. P. et al. Use of oral corticosteroids in the United Kingdom. QJM 93, 105–111 (2000).
Walsh, L. J., Wong, C. A., Pringle, M. & Tattersfield, A. E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313, 344–346 (1996).
Diez-Perez, A. et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 49, 493–498 (2011).
Overman, R. A., Yeh, J. Y. & Deal, C. L. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res. (Hoboken) 65, 294–298 (2013).
Gudbjornsson, B., Juliusson, U. I. & Gudjonsson, F. V. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann. Rheum. Dis. 61, 32–36 (2002).
van Staa, T. P., Leufkens, H. G. & Cooper, C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13, 777–787 (2002).
Kanis, J. A. et al. A meta-analysis of prior corticosteroid use and fracture risk. J. Bone Miner. Res. 19, 893–899 (2004).
van Staa, T. P., Leufkens, H. G., Abenhaim, L., Zhang, B. & Cooper, C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39, 1383–1389 (2000).
Steinbuch, M., Youket, T. E. & Cohen, S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos. Int. 15, 323–328 (2004).
van Staa, T. P., Leufkens, H. G. & Cooper, C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos. Int. 13, 624–629 (2002).
Canalis, E., Mazziotti, G., Giustina, A. & Bilezikian, J. P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319–1328 (2007).
van Staa, T. P., Leufkens, H. G., Abenhaim, L., Zhang, B. & Cooper, C. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15, 993–1000 (2000).
van Staa, T. P., Leufkens, H. G. & Cooper, C. Use of inhaled corticosteroids and risk of fractures. J. Bone Miner. Res. 16, 581–588 (2001).
Leib, E. S. et al. Official positions for FRAX® clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX® of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J. Clin. Densitom. 14, 212–219 (2011).
Etminan, M., Sadatsafavi, M., Ganjizadeh Zavareh, S., Takkouche, B. & FitzGerald, J. M. Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis. Drug Saf. 31, 409–414 (2008).
van Staa, T. P., Bishop, N., Leufkens, H. G. & Cooper, C. Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos. Int. 15, 785–791 (2004).
Loke, Y. K., Cavallazzi, R. & Singh, S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66, 699–708 (2011).
Bijlsma, J. W., Duursma, S. A., Bosch, R., Raymakers, J. A. & Huber-Bruning, O. Acute changes in calcium and bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Br. J. Rheumatol. 27, 215–219 (1988).
Bijlsma, J. W., Duursma, S. A. & Huber-Bruning, O. Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Ann. Rheum. Dis. 45, 757–760 (1986).
van der Veen, M. J. & Bijlsma, J. W. Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis. Clin. Rheumatol. 11, 388–392 (1992).
McEvoy, C. E. et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157, 704–709 (1998).
De Vries, F. et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 56, 208–214 (2007).
Leonard, M. B. et al. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N. Engl. J. Med. 351, 868–875 (2004).
Kanis, J. A., Stevenson, M., McCloskey, E. V., Davis, S. & Lloyd-Jones, M. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol. Assess. 11, 1–231 (2007).
Compston, J. Management of glucocorticoid-induced osteoporosis. Nat. Rev. Rheumatol. 6, 82–88 (2010).
Vestergaard, P., Rejnmark, L. & Mosekilde, L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif. Tissue Int. 82, 249–257 (2008).
Weinstein, R. S. Clinical practice. Glucocorticoid-induced bone disease. N. Engl. J. Med. 365, 62–70 (2011).
Ton, F. N., Gunawardene, S. C., Lee, H. & Neer, R. M. Effects of low-dose prednisone on bone metabolism. J. Bone Miner. Res. 20, 464–470 (2005).
Hayashi, K. et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem. Biophys. Res. Commun. 379, 261–266 (2009).
Yao, W. et al. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 58, 1674–1686 (2008).
den Uyl, D., Bultink, I. E. & Lems, W. F. Advances in glucocorticoid-induced osteoporosis. Curr. Rheumatol. Rep. 13, 233–240 (2011).
Hofbauer, L. C. & Rauner, M. Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol. Endocrinol. 23, 1525–1531 (2009).
Wijenayaka, A. R. et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 6, e25900 (2011).
O'Brien, C. A., Nakashima, T. & Takayanagi, H. Osteocyte control of osteoclastogenesis. Bone 54, 258–263 (2013).
Weinstein, R. S., Jilka, R. L., Parfitt, A. M. & Manolagas, S. C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102, 274–282 (1998).
Kroger, H., Honkanen, R., Saarikoski, S. & Alhava, E. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis—a population based study. Ann. Rheum. Dis. 53, 18–23 (1994).
Roux, C. Are glucocorticoids really deleterious to bone health? Joint Bone Spine 78 (Suppl. 2), S211–S213 (2011).
Vedi, S., Elkin, S. L. & Compston, J. E. A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids. Calcif. Tissue Int. 77, 79–83 (2005).
Zebaze, R. M. et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 375, 1729–1736 (2010).
Compston, J. E. Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Curr. Rheumatol. Rep. 9, 78–84 (2007).
Saag, K. G. et al. Trends in prevention of glucocorticoid-induced osteoporosis. J. Rheumatol. 33, 1651–1657 (2006).
Majumdar, S. R. et al. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998–2008). J. Clin. Endocrinol. Metab. 97, 1236–1242 (2012).
Overman, C. L. et al. Change of psychological distress and physical disability in patients with rheumatoid arthritis over the last two decades. Arthritis Care Res. (Hoboken) 66, 671–678 (2014).
Grossman, J. M. et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. (Hoboken) 62, 1515–1526 (2010).
Lekamwasam, S. et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos. Int. 23, 2257–2276 (2012).
Compston, J. et al. Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos. Int. 19, 1247–1250 (2008).
WHO Collaborating Centre for Metabolic Bone Diseases. FRAX®: WHO Fracture Risk Assessment Tool [online], (2014).
Kanis, J. A., Johnell, O., Oden, A., Johansson, H. & McCloskey, E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385–397 (2008).
Kanis, J. A. et al. Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK. Osteoporos. Int. 19, 1395–1408 (2008).
Kanis, J. A., Johansson, H., Oden, A. & McCloskey, E. V. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos. Int. 22, 809–816 (2011).
Pereira, R. M. et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev. Bras. Reumatol. 52, 580–593 (2012).
National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis (National Osteoporosis Foundation, Washington DC, 2014).
Cohen, S. et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 42, 2309–2318 (1999).
Saag, K. G. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339, 292–299 (1998).
Wallach, S. et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67, 277–285 (2000).
Langdahl, B. L. et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos. Int. 20, 2095–2104 (2009).
Losada, I. et al. Bisphosphonates in patients with autoimmune rheumatic diseases: can they be used in women of childbearing age? Autoimmun. Rev. 9, 547–552 (2010).
van Staa, T. P. et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48, 3224–3229 (2003).
Cooper, C., Dennison, E. M., Leufkens, H. G., Bishop, N. & van Staa, T. P. Epidemiology of childhood fractures in Britain: a study using the general practice research database. J. Bone Miner. Res. 19, 1976–1981 (2004).
Bianchi, M. L. Glucocorticoids and bone: some general remarks and some special observations in pediatric patients. Calcif. Tissue Int. 70, 384–390 (2002).
Marini, J. C. Do bisphosphonates make children's bones better or brittle? N. Engl. J. Med. 349, 423–426 (2003).
Dore, R. K. How to prevent glucocorticoid-induced osteoporosis. Cleve. Clin. J. Med. 77, 529–536 (2010).
Inoue, Y. et al. Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. Clin. Rheumatol. 27, 909–912 (2008).
Nakhla, M. et al. Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children. Clin. Ther. 33, 1516–1523 (2011).
Ward, L. et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database of Systematic Reviews 2007, Issue 4, Art. No.: CD005324. http://dx.doi.org/10.1002/14651858.CD005324.pub2.
Compston, J. Clinical question: what is the best approach to managing glucocorticoid-induced osteoporosis? Clin. Endocrinol. (Oxf.) 74, 547–550 (2011).
Devogelaer, J. P. et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos. Int. 17, 8–19 (2006).
Bischoff-Ferrari, H. A. et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339, b3692 (2009).
Amin, S., LaValley, M. P., Simms, R. W. & Felson, D. T. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum. 42, 1740–1751 (1999).
Homik, J. et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews 1998, Issue 2, Art. No.: CD000952. http://dx.doi.org/10.1002/14651858.CD000952.
Bolland, M. J., Grey, A. & Reid, I. R. Differences in overlapping meta-analyses of vitamin D supplements and falls. J. Clin. Endocrinol. Metab. http://dx.doi.org/10.1210/jc.2014-2562.
de Nijs, R. N. et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 355, 675–684 (2006).
de Nijs, R. N., Jacobs, J. W., Algra, A., Lems, W. F. & Bijlsma, J. W. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos. Int. 15, 589–602 (2004).
Adachi, J. D. et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44, 202–211 (2001).
Shane, E. et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N. Engl. J. Med. 350, 767–776 (2004).
Takeda, S., Kaneoka, H. & Saito, T. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol. Mod. Rheumatol. 18, 271–276 (2008).
Hollick, R. J. & Reid, D. M. Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties. Menopause Int. 17, 66–72 (2011).
Rizzoli, R. et al. Management of glucocorticoid-induced osteoporosis. Calcif. Tissue Int. 91, 225–243 (2012).
Sambrook, P. N. et al. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 50, 289–295 (2012).
Gluer, C. C. et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J. Bone Miner. Res. 28, 1355–1368 (2013).
Adachi, J. D. et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337, 382–387 (1997).
Reid, D. M. et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J. Bone Miner. Res. 15, 1006–1013 (2000).
Reid, D. M., Adami, S., Devogelaer, J. P. & Chines, A. A. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif. Tissue Int. 69, 242–247 (2001).
Reid, D. M. et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373, 1253–1263 (2009).
Devogelaer, J. P. et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J. Rheumatol. 37, 141–148 (2010).
Saag, K. G. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028–2039 (2007).
Saag, K. G. et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60, 3346–3355 (2009).
Farahmand, P. et al. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos. Int. 24, 2971–2981 (2013).
Lane, N. E. et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102, 1627–1633 (1998).
Boutsen, Y., Jamart, J., Esselinckx, W., Stoffel, M. & Devogelaer, J. P. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif. Tissue Int. 61, 266–271 (1997).
Boutsen, Y., Jamart, J., Esselinckx, W. & Devogelaer, J. P. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J. Bone Miner. Res. 16, 104–112 (2001).
Ringe, J. D., Dorst, A., Faber, H., Ibach, K. & Sorenson, F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos. Int. 14, 801–807 (2003).
Mok, C. C. et al. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann. Rheum. Dis. 70, 778–784 (2011).
Hofbauer, L. C. et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140, 4382–4389 (1999).
Sivagurunathan, S., Muir, M. M., Brennan, T. C., Seale, J. P. & Mason, R. S. Influence of glucocorticoids on human osteoclast generation and activity. J. Bone Miner. Res. 20, 390–398 (2005).
Vidal, N. O., Brandstrom, H., Jonsson, K. B. & Ohlsson, C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J. Endocrinol. 159, 191–195 (1998).
Weinstein, R. S. et al. Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. Endocrinology 152, 3323–3331 (2011).
Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231–1234 (2011).
Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235–1241 (2011).
Cohen, S. B. et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58, 1299–1309 (2008).
Dore, R. K. et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann. Rheum. Dis. 69, 872–875 (2010).
Jia, J. et al. Glucocorticoid dose determines osteocyte cell fate. FASEB J. 25, 3366–3376 (2011).
Stoch, S. A. & Wagner, J. A. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin. Pharmacol. Ther 83, 172–176 (2008).
Eisman, J. A. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J. Bone Miner. Res. 26, 242–251 (2011).
van Lierop, A. H., Hamdy, N. A. & Papapoulos, S. E. Glucocorticoids are not always deleterious for bone. J. Bone Miner. Res. 25, 2796–2800 (2010).
Gerber, A. N., Masuno, K. & Diamond, M. I. Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. Proc. Natl Acad. Sci. USA 106, 4929–4934 (2009).
Rauch, A. et al. An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J. 25, 1323–1332 (2011).
Bone and Tooth Society of Great Britain, National Osteoporosis Society, Royal College of Physicians. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment (RCP, London, 2002).
Geusens, P. P. et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann. Rheum. Dis. 63, 324–325 (2004).
Nawata, H. et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J. Bone Miner. Metab. 23, 105–109 (2005).
Dachverband Osteologie. DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteologie 20, 55–74 (2011).
Papaioannou, A. et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182, 1864–1873 (2010).
Compston, J. et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75, 392–396 (2013).
No authors listed. Actualisation 2012 des recommandations françaises du traitement médicamenteux de l'ostéoporose po-ménopausique [online]
Acknowledgements
The authors thank K. Giroux for her secretarial assistance.
Author information
Authors and Affiliations
Contributions
Both authors contributed equally to researching data for the article, made substantial contributions to discussion of content, writing and reviewing/editing of the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Rizzoli, R., Biver, E. Glucocorticoid-induced osteoporosis: who to treat with what agent?. Nat Rev Rheumatol 11, 98–109 (2015). https://doi.org/10.1038/nrrheum.2014.188
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2014.188
- Springer Nature Limited
This article is cited by
-
Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy
Osteoporosis International (2024)
-
Chronic arthritides and bone structure: focus on rheumatoid arthritis—an update
Aging Clinical and Experimental Research (2023)
-
Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update
Aging Clinical and Experimental Research (2022)
-
Prevalence of osteoporosis among the elderly population of Iran
Archives of Osteoporosis (2021)
-
Correlation between continuation of glucocorticoid treatment and risk of femoral head collapse
Der Orthopäde (2021)